MicroRNA-16 Restores Sensitivity to Tyrosine Kinase Inhibitors and Outperforms MEK Inhibitors in KRAS-Mutated Non-Small Cell Lung Cancer

Background: Non-small cell lung cancer (NSCLC) is the leading cause of cancer death worldwide. Chemotherapy, the treatment of choice in non-operable cases, achieves a dismal success rate, raising the need for new therapeutic options. In about 25% of NSCLC, the activating mutations of the KRAS oncoge...

Descripción completa

Detalles Bibliográficos
Autores principales: Fanini, Francesca, Bandini, Erika, Plousiou, Meropi, Carloni, Silvia, Wise, Petra, Neviani, Paolo, Murtadha, Mariam, Foca, Flavia, Fabbri, Francesco, Vannini, Ivan, Fabbri, Muller
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705178/
https://www.ncbi.nlm.nih.gov/pubmed/34948154
http://dx.doi.org/10.3390/ijms222413357

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705178/
https://www.ncbi.nlm.nih.gov/pubmed/34948154
http://dx.doi.org/10.3390/ijms222413357

Ejemplares similares